Sign Out
Pharmacology: Pharmacodynamics: Menotrophin (Gynogen HP), administered for 7 to 20 days, produces ovarian follicular growth and maturation in women who do not have primary ovarian failure. In order to produce final follicular maturation and ovulation in the absence of an endogenous LH surge, hCG must be administered following Menotrophin (Gynogen HP) treatment, at a time when patient monitoring indicates sufficient follicular development has occurred.
Pharmacokinetics: Absorption: The SC route of administration trends toward greater bioavailability than the IM route for single and multiple dose of Menotrophins (Gynogen HP).
Distribution: Human tissue or organ distribution of FSH and LH has not been studied for Menotrophin (Gynogen HP).
Metabolism: Metabolism of FSH and LH has not been studied for in humans.
Pediatric Populations: Menotrophin (Gynogen HP) has not been studied in the pediatric population.
Geriatric Population: Menotrophin (Gynogen HP) has not been studied in the geriatric population.
Special Populations: The safety and efficacy of Menotrophin (Gynogen HP) in renal and hepatic insufficiency has not been studied.
Continue with Google